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Exposure of Neospora caninum tachyzoites to BKI-1294 in vitro results in the formation
of long-lived multinucleated complexes (MNCs). However, in vivo treatment of BALB/c
mice with BKI-1294 shortly after N. caninum infection during pregnancy was safe and
profoundly reduced pup mortality and vertical transmission. We hypothesized that the
formation of MNCs could trigger immune responses that contribute to BKI efficacy in vivo.
In this study, mice were first vaccinated with a sublethal dose of N. caninum tachyzoites
and were treated with BKI-1294. We then investigated the effects of these treatments
after mating and re-infection during pregnancy. Effects on fertility, pup survival, vertical
transmission, and parasite load in dams were evaluated. Cytokines in sera or splenocyte
culture supernatants were assessed by either ELISA or the LuminexTM 200 system, and
humoral immune responses against tachyzoite and MNC antigens were compared by
ELISA, Western blotting and immunoproteomics. Our results showed that BKI-1294
treatment of live-vaccinated mice reduced the cerebral parasite load in the dams, but
resulted in higher neonatal pup mortality and vertical transmission. In live-vaccinated
mice, cytokine levels, most notably IFN-y, IL-10, and IL-12, were consistently lower
in BKI-1294 treated animals compared to non-treated mice. In addition, comparative
Western blotting identified two protein bands in MNC extracts that were only recognized
by sera of live-vaccinated mice treated with BKI-1294, and were not found in tachyzoite
extracts. We conclude that treatment of live-vaccinated mice with BKI-1294 influenced
the cellular and humoral immune responses against infection, affected the safety of
the live-vaccine, and decreased protection against re-infection and vertical transmission
during pregnancy.
Keywords: neosporosis, mouse model, bumped kinase inhibitor, calcium-dependent protein kinase, immune
response, live-vaccine, real time PCR, proteomics
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INTRODUCTION
The apicomplexan parasite Neospora caninum is an important
causative agent of abortion or birth of weak offspring in cattle,
and to a lesser extent in sheep and other ruminants (1). The
sexual cycle of N. caninum takes place in canine intestinal
tissue, and dogs do not only shed oocysts which become
infective after sporulation, but can also act as intermediate
hosts and become affected by neurological symptoms. Rapidly
proliferating tachyzoites represent the disease-causing stage that
can cross the placenta and infect the fetus. Upon infection of an
immunocompetent host, differentiation into tissue-cyst-forming
bradyzoites takes place, which remain viable, proliferate slowly,
and do not cause inflammation. Infection of fetuses during
pregnancy occurs via exogenous transplacental transmission
in cases where primary maternal infection takes place during
the course of the pregnancy, or endogenous transplacental
transmission in cases where persistently infected animals
undergo pregnancy-driven immunomodulation that leads to
recrudescence and bradyzoite-tachyzoite reconversion (2, 3).
Currently there is no vaccine on the market for the prevention of
bovine or canine neosporosis and so far, no immuno- or chemo-
therapeutic treatments have found their way to the market.
However, live-vaccines comprised of low-virulence strains of N.
caninum strains have shown promising efficacy in both murine
and bovine models (4–8).
Protein kinases are involved in functional activities that
control essential aspects of apicomplexan biology, including
host cell invasion, intracellular proliferation, and egress (9–
11). Calcium-dependent protein kinases (CDPKs) are especially
interesting drug targets in that homologs of CDPKs are not
found in mammals. One of these kinases is CDPK1, homologs of
which are intensively studied in target-based drug development
for a wide range of apicomplexans including Plasmodium,
Cryptosporidium, Eimeria, Babesia, Theileria, Toxoplasma, and
Neospora among others [reviewed by (12, 13)]. In N. caninum
and T. gondii, CDPK1 is essential for motility, host cell invasion,
and egress of tachyzoites from the host cell, through its role in the
signaling events that control microneme secretion (14, 15).
Bumped kinase inhibitors (BKIs) are ATP-competitive
CDPK1 inhibitors. They exhibit a high degree of efficacy and
specificity for apicomplexan CDPK1, as they are optimized to
fit their C-3 bulky aromatic substituents into a hydrophobic
pocket behind the atypically small gatekeeper residue. This large
hydrophobic pocket is absent in most mammalian kinases ATP
binding sites (16). The specificity of many BKIs is further
mediated by binding to the hinge region of the active site of
CDPK1, similar to the binding motif of ATP while maintaining
additional hydrogen bond interaction with residues in the ribose
pocket (17, 18). Several BKIs have been studied so far with
respect to efficacy against N. caninum infection, including the
pyrazolopyrimidine BKI-1294. BKI-1294 interferes with host
cell invasion and egress, but does not act parasiticidal in
vitro (19). BKI-1294 also affects the intracellular tachyzoites by
inducing the formation of multinucleated complexes (MNCs)
(20), which are characterized by continued nuclear division,
and the formation of intracellular zoites separated by the inner
membrane complex, but lacking the major surface antigen 1
(SAG1) (21). However, these zoites failed to undergo disjunction
and tachyzoite formation, remained trapped within the host cell
cytoplasm, and exhibited altered mRNA and protein expression
(19, 22). MNCs remained viable for up to 20 days under constant
BKI-1294 drug pressure in vitro, and upon drug removal the
block in zoite disjunction was alleviated and new infective
tachyzoites were formed, which resumed proliferation (21).
Nevertheless, BKI-1294 is very effective in vivo, and in
pregnant mice treatment strongly increased pup survival and
inhibited exogenous transplacental transmission of N. caninum
(19) in an efficient manner. BKI-1294 was also efficacious in
pregnant mice and in pregnant sheep infected with the closely
related Toxoplasma gondii (23, 24). Other MNC-inducing BKIs
such as BKI-1517 and BKI-1553 were also effective against
neosporosis, as shown in pregnant mouse and sheep models
(25, 26). All these earlier studies focused on treatments to prevent
exogenous transplacental transmission of N. caninum. We here
show that BKI-1294 therapy in live-vaccinated, thus already
infected, mice has a negative impact on the safety and the
protective activity against challenge infection during pregnancy,
and this is accompanied by alterations in cellular and humoral
immune responses in live-vaccinated mice. Thus, the use of BKI-
1294 in N. caninum infected animals could have detrimental
effects upon re-infection during pregnancy.
MATERIALS AND METHODS
Tissue Culture and Media, Biochemicals,
and Drugs
If not stated otherwise all tissue culture devices were purchased
from Sarstedt (Sevelen, Switzerland), culture media were from
Gibco-BRL (Zürich, Switzerland) and biochemicals were from
Sigma (St. Louis, MO). Molecular biology kits were obtained
from Qiagen (Hilden, Germany). BKI-1294 was synthesized to
>99% purity by NMR and HPLC by Wuxi AppTec (Shanghai,
China), in a method that was previously described (27). For in
vitro treatments, BKI-1294 was stored as a 20mM stock solution
in dimethyl sulfoxide (DMSO) at−20◦C; for application in mice,
BKI-1294 powder was suspended in corn oil, and the suspension
was applied by gavage.
Host Cell and Parasite in vitro Culture
Human foreskin fibroblasts (HFF; ATCC R© SCRC-1041TM)
and BALB/c dermal fibroblasts (ATCC R© CCL-163) were
maintained in Dulbecco’s modified Eagle medium (DMEM,
high glucose, GlutaMAXTM Supplement, HEPES), and the
monkey kidney cell line Marc-145 (ATCC R© CRL-12231)
was cultured in DMEM without sodium pyruvate and
HEPES. Media were supplemented with phenol red, 10%
heat-inactivated and sterile filtered fetal calf serum (FCS),
50U of penicillin/ml, and 50 µg streptomycin / ml. The
N. caninum isolates Nc-Liverpool (NC-Liv) and Nc-Spain7
(Nc-Sp7) were maintained by infecting semi-confluent HFF
or Marc-145 monolayers and culture at 37◦C/5% CO2, with
passages once or twice per week. To obtain tachyzoites for
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infection of BALB/c mice, infected monolayers were washed
in medium without serum, and scraped from tissue culture
flasks when tachyzoites were still largely intracellular (>90% of
undisrupted parasitophorous vacuoles). They were repeatedly
passed through a 25-gauge needle, liberated parasites were
suspended in 0.2% trypan blue in PBS and counted in a
hemocytometer. They were used for infection experiments when
at least >95% viable.
Ethical Statement
Animal studies were approved by the AnimalWelfare Committee
of the Canton of Bern under the license BE96/117. BALB/c mice
were purchased from Charles River (Sulzberg, Germany), and
were housed in a common room, under controlled temperature
and a 14 h dark/10 h light cycle, with food and water ad libitum,
according to guidelines of animal welfare legislation of the Swiss
Veterinary Office. The animals were handled in strict accordance
with practices to minimize suffering.
Live-Vaccination and BKI-1294 Treatments,
and Re-infection of BALB/c Mice During
Pregnancy
Eighty-eight (88) female and 44 male BALB/c mice, 6–8 weeks
of age, were used in the experiment. Females were randomly
assigned to 6 experimental groups (treatment groups A-E: 16
females/group). The experimental treatments for each group
are summarized in Table 1, and a timeline for all treatments
is shown in Supplementary Figure 1. On day 0, 4 groups (A–
D) were live-vaccinated by subcutaneous (s.c.) injection of 105
Nc-Liv tachyzoites, while groups E and F remained uninfected
and mock-vaccinated with PBS. Groups B and C received BKI-
1294 treatments (50 mg/kg in corn oil by gavage) on a daily
basis for 5 days, starting on day 2 post-live-vaccination, the
other groups received corn oil only. All animals were mated
during days 21–23, with one male assigned to two females.
Groups C, D, and E were subsequently re-infected on day 28,
by s.c. inoculation of 2 × 105 Nc-Sp7 tachyzoites (28, 29). After
TABLE 1 | Experimental groups for the assessment of BKI-1294 treatment effects
in N. caninum infected mice, mated and re-challenged or not during pregnancy.
Groupsa Live vaccine BKI-1294 Mating/pregnancy Re-challenge
day 0b d2-7c d21-23 day 28d
A (v, t, i) Yes yes yes Yes
B (v, t, –) Yes yes yes No
C (v, –, i) Yes no yes Yes
D (v, –,–) Yes no yes No
E (–, –, i) No no yes Yes
F (–, –, –) No no yes No
av, vaccinated; t, BKI-1294 treated; i, infected during pregnancy; n = 16 for all groups.
bs.c. infection with 1 × 105 Nc-Liv tachyzoites.
cDaily application by gavage of BKI-1294, 50 mg/kg/day during 5 days.
ds.c. infection with 2 × 105 Nc-Sp7 tachyzoites during pregnancy.
separation of pregnant from non-pregnant mice on day 36 post-
infection (p.i.), dams were put into individual cages and gave
birth on days 40–42 post-infection (p.i.). They were allowed to
rear their pups and were closely monitored for 30 days. On day
72, all surviving animals were euthanized in a chamber floated
with the anesthetic isoflurane, followed by CO2. The brain was
dissected and frozen at −80◦C for subsequent determination of
the cerebral parasite burden. Blood was collected at 3 timepoints
during this experiment: from the tail vein 14 days post live-
vaccination and on day 16 of pregnancy, and by heart puncture
on day 30 post-partum.
Determination of the Cerebral Parasite
Burden by Real Time PCR
The cerebral parasite burden of dams and surviving pups
was analyzed by N. caninum-specific real-time PCR of
brain tissue DNA as previously described (29, 30). DNA
extraction was performed using the Nucleospin Kit (Macherey-
Nagel, Oensingen, Switzerland). The DNA concentration was
determined using the QuantiFluor dsDNA System (Promega,
Madison, Wi., USA) and was adjusted to 5 ng/ml with sterile
DNase free water. The sequence of the forward primer P-
NEO-PF1 was 5′-CCCAGTGCGTCCAATCCTGTAAC-3′,
the sequence of the reverse primer P-NEO-PR1 was 5′-CTCG
CCAGTCAACCTACGTCTTCT-3′. Fluorescent probes were
P-NEO-SO3FL (5′-CACGTATCCCACCTCTCACCGCTACCA-
3′) and P-NEO-SO5LC (5′-TCCCTCGGTTCACCCGTTCAC
ACAC-3′). Quantitative real-time PCR was performed using the
Rotor-Gene 6000 real-time PCR machine. The parasite load was
calculated by interpolation from a standard curve with DNA
equivalents from 1,000, 100, and 10 N. caninum tachyzoites
included in each run.
Preparation of N. caninum Tachyzoite- and
MNC-Extracts
Tachyzoite and MNC preparations were done essentially
as described (22). In short, semi-confluent BALB/c dermal
fibroblast monolayers were maintained in T175 cell culture flasks
infected with 106 Nc-Liv tachyzoites and passaged at least twice
prior to the experiment. At 4 h post infection, treatment with
5µM BKI-1294, or the corresponding amount of DMSO in
controls, was initiated. Cultures were maintained at 37◦C/5%
CO2 during 3 days for generating tachyzoites as DMSO-treated
controls, or during 6 days in the presence of BKI-1294 for
generating MNCs. Subsequently, the infected monolayers were
washed twice with PBS, followed by removal of infected cells with
a rubber cell scraper and resuspension in PBS. After passaging
the suspensions twice through a 25-gauge needle to break the
host cells. MNCs and tachyzoites were separated from host cell
debris by Sephadex G-25 chromatography as described (31).
The parasite fractions in the flow through were collected by
centrifugation (15min, 1,000 × g, 4◦C) and washed twice with
PBS. The protein content was measured with a PierceTM BCA
Assay Kit (ThermoFisher Scientific, Reinach, Switzerland) and
samples were stored at−80◦C.
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Analysis of IgG1 and IgG2 Responses by
Enzyme Linked Immunosorbent Assay
(ELISA)
The levels of IgG1 and IgG2a were measured by ELISA as
previously described (32). Briefly, 96-well-plates were coated
overnight at 4◦C with 200 ng of N. caninum tachyzoite extract
in 100 µl coating buffer per well. The extract was obtained by
subjecting tachyzoites to three freeze–thaw cycles and sonication
for 4 x 30 s at 57W before being filtered through a 20µm sterile
filter. After three washes, plates were blocked with 1% bovine
serum albumin in wash buffer [PBS with 0.05% Tween-20 (v/v)]
and serum samples (4 replicates per sample) were applied at room
temperature (RT). After three washes, plates were incubated with
either goat anti-mouse IgG1 or IgG2a conjugated to alkaline
phosphatase (AP) (SouthernBiotech, Birmingham, USA). The
reaction was developed with AP substrate and absorbance values
as optical density (OD) at 405 nm read in a tunable microplate
reader (EnSpireTM 2300Multilabel Reader, Switzerland). In order
to compare OD values between samples analyzed in different
plates, the same positive and negative serum controls were added
in each plate and OD values for each sample were converted into
a relative index per cent (RIPC) using the following formula RIPC
= (OD405 sample-OD405 negative control)/(OD405 positive
control-OD405 negative control) (33).
Measurements of the Direct Impact of
BKI-1294 on Splenocyte Proliferation
Splenocyte proliferation assays were carried-out as previously
described (34). Briefly, splenocytes were isolated from female
BALB/c mice and were distributed in polystyrene 96 well-flat
bottom plates at 2 × 105 cells/100 µL/well. Splenocytes were
either left unstimulated or were stimulated with Concanavalin
A (ConA, 5µg/mL), lipopolysaccharide (LPS, 10µg/mL), ConA
plus 0.4µM BKI-1294 or 0.3µM pyrimethamine (Pyr), or LPS
plus 0.4µM BKI-1294 or 0.3µM Pyr. Each assay was done in
quadruplicates. Cultures were maintained in a 37◦C humidified
chamber containing 5% CO2 for a total incubation period of
72 h. Proliferation of splenocytes was measured using a 5-bromo-
20-deoxy-uridine (BrdU) cell proliferation kit (QIA58, Merck
Millipore). Data are presented as mean ± standard deviation
(SD) for the indicated numbers.
Measurements of Cytokine Levels in Sera
and in Splenocyte Culture Supernatants by
Multiplex Immunoassay
BALB/c mice (6 animals/group) were live-vaccinated by s.c.
inoculation of 105 Nc-Liv tachyzoites as above, and treated with
BKI-1294 or not, as described in above. Blood samples (max.
100 µl) were collected from the tail vein 4 days p.i (after 2 days
of treatment), 11 days p.i. (5 days post-treatment stop), and by
cardiac puncture at 26 days p.i. (20 days post treatment-stop)
following euthanasia. Splenocytes obtained after euthanasia were
cultured in vitro and were stimulated withN. caninum tachyzoite
extract or remained unstimulated, and medium supernatants
were collected after 72 h and stored at −80 ◦C. Luminex
xMAP technology (35) was used for determination of cytokines,
chemokines, and growth factors from pooled medium and
serum samples from the 6 animals. The multiplexing analysis
was performed using the LuminexTM 200 system (Luminex,
Austin, TX, USA) by Eve Technologies Corp. (Calgary, Alberta).
Measurements were done using Eve Technologies’ Mouse
Focused 10-Plex Discovery Assay R© (MilliporeSigma, Burlington,
Massachusetts, USA) according to the manufacturer’s protocol.
The 10-plex consisted of GM-CSF, IFNγ, IL-1β, IL-2, IL-4, IL-
6, IL-10, IL-12 (p70), MCP-1, and TNFα. Assay sensitivities
of these markers range from 0.4 to 10.9 pg/ml. Individual
analyte sensitivity values are available in the MilliporeSigma
MILLIPLEX R© MAP protocol.
SDS-PAGE and Western Blotting
BALB/c mice, 4 animals per group, were live-vaccinated as above,
and treated with BKI-1294 (50 mg/kg/day for 5 days) or with
corn oil alone as described above. Mice were euthanized on day
26 p.i., and blood was collected by heart puncture. The sera
of each group were pooled and stored at −20◦C prior to use.
Tachyzoite and MNC fractions (see above) were taken up in
SDS-sample buffer to reach a protein concentration of 1µg/ml,
and 20 µl of each extract was separated by preparative 8% SDS-
PAGE, using a Hoefer Minigel 250 Apparatus (GE Healthcare,
Little Chalfont, UK). Gels were either silver stained (36), or
Western blotting onto polyvinylidene difluoride membrane was
carried out using a Hoefer TE22 Mighty Small Transphor, for
1 h at 100V (21). The membrane was cut vertically into small
strips, and selected strips were blocked for 1 h at RT in PBS/0.1%
Tween-20/2% milk powder, while the remaining strips were air-
dried and stored at RT in the dark. The blocked strips of each
fraction were then incubated with serum from live-vaccinated
+ BKI-1294 treated mice or non-treated mice (both diluted
1:100 in blocking buffer, 15 h, 4◦C). Following washes in PBS-
Tween, the strips were incubated with anti-mouse IgG (H&L)
Alkaline Phosphatase (AP) conjugate (Promega, Madison, USA)
at a dilution of 1:2,000 in blocking solution for 1 h at RT.
Bound antibodies were visualized by a color reaction using 0.3%
BCIP/NBT stock solution (Roche, Germany) in AP development
buffer (0.1M NaCl, 5mM MgCl2, and 0.1M Tris pH 9.5). Prior
to drying at RT and alignment of the strips, they were washed
extensively with H2O.
Immunoproteomics
In order to identify proteins that are present in bands specifically
recognized in MNC extract, strips were carefully aligned and the
specifically labeled bands in MNC extracts, as well as the non-
labeled areas of identical molecular mass in tachyzoite extracts,
were cut out and their protein composition was analyzed at
the Mass Spectrometry and Proteomics Facility, Department of
Clinical Research, University of Bern. For this, each band was
further cut into fragments of 1 mm2, blocked in 0.5% PVP-40,
reduced, alkylated and digested with trypsin. The digests were
analyzed by liquid chromatography (LC)-MS/MS (PROXEON
coupled to a QExactive HF mass spectrometer, ThermoFisher
Scientific) with one injection of 5 µl digests. Peptides were
trapped on aµPrecolumnC18 PepMap100 (5µm, 100Å, 300µm
× 5mm, ThermoFisher Scientific) and separated by backflush on
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a C18 column (5µm, 100 Å, 75µm × 15 cm, C18) by applying a
20-min gradient of 5% acetonitrile to 40% in water, 0.1% formic
acid, at a flow rate of 300 nl/min. The Full Scan method was
set with resolution at 60,000 with an automatic gain control
(AGC) target of 1E06 and maximum ion injection time of 50ms.
The data-dependentmethod for precursor ion fragmentation was
applied with the following settings: resolution 15,000, AGC of
1E05, maximum ion time of 110 milliseconds, mass window 1.6
m/z, collision energy 27, under fill ratio 1%, charge exclusion
of unassigned and 1+ ions, and peptide match preferred,
respectively. Spectra interpretation was performed with Easyprot
on a local server run under Ubuntu against a forward + reverse
Neospora caninum Liverpool database, using fixed modifications
of carboamidomethylated on Cys, and variable modification of
oxidation on Met, and acetylation on protein N-Term. Parent
and fragment mass tolerances were set to 10 ppm and 0.4 Da,
respectively. Matches on the reversed sequence database were
used to set a Z-score threshold, where 1% false discoveries on
the peptide spectrum match level had to be expected. Protein
identifications were only accepted, when two unique peptides
fulfilling the 1% FDR criterium were identified.
Statistics
The percentages of survivors and vertical transmission at the end
of the experiment or percentages of N. caninum PCR positive
samples were analyzed by Chi-square test with Yates’ continuity
correction in a contingency table. Statistical analysis of the
parasite burdens in brains was done using the Kruskal–Wallis test
followed by the Wilcoxon rank-sum test with Holm adjustment.
Differences in humoral immune responses were assessed by
Kruskal-Wallis or U Mann-Whitney test.
RESULTS
Effects of BKI-1294 Treatment in
Live-Vaccinated Mice Re-infected With N.
caninum Tachyzoites During Pregnancy
The structure to study the impact of BKI-1294 treatment in live-
vaccinated mice consisted of 6 groups (A–F) and is shown in
Table 1. The outcome of this study is summarized in Table 2.
Groups A–D were live vaccinated with an infection dose of 105
Nc-Liv tachyzoites, and none of the mice exhibited clinical signs
or succumbed to disease during the entire experiment. The live-
vaccinated groups (A–D) exhibited similar fertility rates (50–
80%) as the non-infected mice (groups E and F). Litter sizes
ranged between 4.9 and 5.8 pups/dam. Live vaccination without
further treatments as shown in group D led to survival of all
pups, and no vertical transmission occurred, demonstrating the
safety of this live vaccination approach. However, treatment
with BKI-1294 following live vaccination (group B) resulted in
12.5% neonatal mortality, but postnatal mortality was restricted
to only 1 pup out of 56, and vertical transmission occurred in
6 out of 56 pups. As can be seen in group C, live vaccination
was also very efficacious in terms of protection against re-
infection during pregnancy, with neonatal mortality detected in
only 2 out 57 pups, but no cases of postnatal mortality, and
also no vertical transmission. In contrast, BKI-1294 treatment
(group A) decreased protection against re-infection during
pregnancy, especially with regard to vertical transmission, as it
was detected in over 21% (8 out of 37) of the pups, which was
significantly higher than in group C (P < 0.05). The highest
rates of neonatal and postnatal mortality were seen in group E,
which was only challenge-infected during pregnancy. Overall,
applying BKI-1294 treatment following live-vaccination lead to
a partial deterioration of the safety as well as the efficacy of the
live vaccine.
The cerebral parasite load in the dams at 30 days post-
partumwas determined by quantitative real time PCR (Figure 1),
and was significantly elevated in group E compared to all
other groups. In group B (live vaccinated and BKI-1294 treated
without re-infection), cerebral parasite loads in the dams were
significantly lower compared to those groups that were not
BKI-1294 treated, namely group C (live-vaccinated and then
re-infected), and group D (only live-vaccinated).
Antibody responses against N. caninum antigens were
assessed by ELISA at three timepoints (Figure 2): (i) 14 days post
live-vaccination and 12 days post-BKI-1294 treatment); (ii) on
day 16 of pregnancy; and (iii) on day 30 post-partum. Antibody
levels measured prior to pregnancy (Figure 2A) were below
those at the later timepoints. However, IgG1 levels in groups
A-B (treated with BKI-1294) were significantly lower compared
to groups C-D (non-treated), while IgG2a levels were similar.
At 16 days of pregnancy, 8 days after the mice had been re-
challenged (Figure 2B), groups A and C, both live vaccinated and
re-challenged, exhibited higher IgG1 levels compared to groups
B and D, which had been only live-vaccinated but were not re-
infected during pregnancy, indicating that re-infection induced
an antibody response. No significant difference in IgG1 levels
could be seen in the corresponding BKI-1294 treated groups A
and B, and no antibody response could be measured in group E
at this timepoint. However, at 30 days post-partum (Figure 2C),
IgG1 and IgG2 levels in group E (challenged only once during
pregnancy) were significantly higher compared to groups B and
D, which both were only live vaccinated, either with (group
B) or without (group D) subsequent BKI-1294 treatment. A
comparison of the IgG1/IgG2a ratios at day 16 of pregnancy
(Figure 2D) revealed that those groups that were live-vaccinated
and re-infected (groups A and C) exhibited a predominantly
IgG1-biased response, which wasmuch less pronounced in group
A (treated with BKI-1294 following live vaccination). In contrast,
those groups that were only live-vaccinated without re-infection
(B and D), exhibited IgG2a-biased responses, independent of
treatment. On day 30 post-partum (Figure 2E), the IgG1/IgG2a
ratios in groups A and C were more balanced, similar to group E,
and in group B and D (only live-vaccinated) the IgG2a-bias was
maintained (Figure 2E).
Effects of BKI-1294 Treatment on the
Cellular Immune Response in
Live-Vaccinated Mice
We first investigated whether BKI-1294 itself could have a direct
impact on the proliferative capacities of B- or T- cells. For this,
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TABLE 2 | Outcome of N. caninum infection in live-vaccinated and/or non-vaccinated pregnant mice, treated or not with BKI-1294 prior to challenge infection during
pregnancy.
Groupa Fertility (%)b Litter size (pups/dam)c Neonatal mortality (%)d Postnatal mortality (%)e Postnatal survival (%)f Vertical transmission (%)g
A (v; t, i) 8/16 (50) 39 (4.9) 2/39 (5.1) 3/37 (8.1) 34/37 (91.9) 8/37 (21.6)
B (v, t, –) 13/16 (80) 64 (4.9) 8/64 (12.5) 1/56 (1.8) 55/56 (98.2) 6/56 (10.7)
C (v, –, i) 11/16 (70) 57 (5.1) 2/57 (3.5) 0/55 (0) 55/55 (100) 0/55 (0)
D (v, –, –) 12/16 (75) 69 (5.8) 0/69 (0) 0/69 (0) 69/69 (100) 0/69 (0)
E (–, –, i) 12/16 (75) 58 (4.8) 8/58 (13.8) 46/50 (92) 4/50 (8) 48/50 (96)
F (–, –, –) 8/16 (50) 40 (5) 2/40 (5) 0/38 (0) 38/38 (100) 0/38 (0)
av, vaccinated; t, BKI-1294 treated; i, infected during pregnancy.
bProportion of pregnant mice per group (%).
cNumber of delivered pups per dam.
dProportion of pups born dead or that died within the first 2 days post-partum (%).
eProportion of pups died from day 3 to 30 post-partum (%).
fProportion of survival pups at day 30 post-partum (%).
gProportion of Neospora caninum-PCR positive surviving pups plus those which died from day 3 post-partum [dead pups from day 3 post-partum are considered N. caninum-PCR
positive as previously shown (37)].
FIGURE 1 | Cerebral parasite loads in the dams of the different treatment groups measured by quantitative real time PCR and presented as box plots. The table
shows the results of the statistical evaluation, p-values in red indicate significant differences; v = vaccinated; t = BKI-1294 treated; i = infected during pregnancy; -
indicates no treatment; n = 16 for all groups.
naïve BALB/c mouse splenocytes were isolated and cultured in
vitro and were treated with ConA (for T cell stimulation) or
LPS (for B cell stimulation), and 0.4µM BKI-1294 or 0.3µM
pyrimethamine were added concomitantly to the mitogens. After
an additional 72 h in culture, no inhibitory effect on ConA or
LPS-induced proliferation of splenocytes was visible in BKI-1294
treated cultures, while pyrimethamine inhibited the proliferation
of B cells by almost 50% (Figure 3).
Subsequently, the potential impact of BKI-1294 treatment on
the cellular immune response in mice live-vaccinated with N.
caninum was studied by assessing cytokine levels in medium
supernatants of splenocytes cultured with or without stimulation
with crude N. caninum antigen extract (Nc-antigen). For this,
live-vaccinated BALB/c mice were treated either with BKI-
1294 emulsified in corn oil, or corn oil alone, during 5
days, starting at 2 days p.i. None of the animals showed any
clinical signs throughout the observation period. Following
euthanasia splenocytes from each treatment group were cultured
in vitro and were stimulated with Nc-antigen or remained
unstimulated. Medium supernatants were collected after 3 days,
and subjected to cytokine analysis. The results are summarized
in Table 3. Medium supernatants obtained from non-stimulated
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FIGURE 2 | Humoral immune responses in the pregnant mice of the different treatment groups A–E. Group F is omitted, since these animals were not infected. Blood
was collected at 14 days post-live vaccination (A), on day 15 of pregnancy = day 8 post-re-challenge infection (B), and on day 30 post-partum = 40 days after
re-challenge (C). In panel A, groups A and B (both live-vaccinated and treated), C and D (both live-vaccinated but not treated) and E and F (both non-vaccinated and
not treated) were grouped together, as at this time point animals from these groups had undergone the same treatments. Antibody levels on the y-axis are indicated
as relative index per cent (RIPC) values) * indicates P <0.05. (D,E) Show IgG1/IgG2a ratios in the different treatment groups at day 15 of pregnancy (E) and day 30
post-partum (F).
FIGURE 3 | Direct effects of BKI-1294 and pyrimethamine on proliferation of LPS- and ConA treated murine splenocytes. Bars represent standard deviation from the
mean of four replicates. A 100% of proliferation is attributed to controls (ConA and LPS); values indicate percent of proliferation compared to control (*) p < 0.01 in
relation to controls (ConA or LPS). Proliferation (A,B) was assessed by BrdU incorporation.
control splenocyte cultures showed consistently lower cytokine
levels compared to Nc-antigen stimulated cultures. The highest
concentrations by far were measured for IFN-γ, which were
higher in Nc-antigen stimulated splenocytes of non-treated mice
compared to BKI-1294 treated mice. For splenocyte cultures of
live-vaccinated mice that were not BKI-1294 treated, cytokine
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TABLE 3 | Cytokine levels (pg/ml) measured in medium supernatants of splenocytes obtained from live-vaccinated mice on day 26 p.i., as determined by multiplex
immunoassay.
IFNy IL-1b GM CSF IL-2 IL-4 IL-6 IL-10 IL-12 MCP-1 TNFa
Nc-antigen +BKI-1294 50000* 24.4 1089.6 272.8 455.3 1231.2 3521.2 22.8 557.8 169.7
Nc-antigen –BKI-1294 70000* 25.6 866.6 216.6 818.3 979.8 4373.7 31.4 730.2 139.9
non-stim +BKI-1294 1354.8 9.1 686.5 1132.9 87.4 373.0 155.8 4.4 540.5 29.0
non-stim –BKI-1294 1077.9 9.1 709.0 1217.5 79.8 286.9 118.3 21.5 602.2 20.7
Live-vaccinated mice were either treated by oral application of BKI-1294 (50 mg/kg/day for 5 days), starting on day 2 p.i.. Individual values are from 6 pooled medium supernatants of
splenocyte cultures that were either stimulated with N. caninum tachyzoite extract (Nc-antigen, 10µg/ml) or remained non-stimulated (non-stim).
*The concentrations of IFN-y are exceedingly high and estimated values are shown. Measurements were done on pooled samples from 6 mice, using Eve Technologies’ Mouse Focused
10-Plex Discovery Assay® (MilliporeSigma, Burlington, Massachusetts, USA).
concentrations were higher, with the exception of GM CSF, IL-2,
IL-6, and TNF-alpha.
Cytokine levels were also determined in serum samples
collected from N. caninum infected untreated and BKI-1294
treated BALB/c mice at 4, 11, and 26 days p.i. (corresponding
to day 2 of treatment and days 4 and 21 post-treatment,
respectively). The results for selected cytokines on days 11
and 26 are shown in Figure 4, and values for all cytokines at
all timepoints are shown in Table 4. At 4 days p.i., cytokine
levels were still low in both groups (max 34 pg/ml), thus no
differences were noted between live-vaccinated and BKI-1294-
treated and non-treated mice. More pronounced changes were
seen on day 11 p.i., (Figure 4A), with 5–6 times higher IFN-
γ levels in the placebo treated / live-vaccinated group (253
pg/ml) compared to the BKI-1294-treated / infected group (42
pg/ml). However, elevated IL-10 (67–94 pg/ml), IL-12 (235–
278 pg/ml), and MCP-1 levels (83–86 pg/ml) were also noted
in all 4 groups at that intermediate timepoint. On day 26 p.i.
(Figure 4B), IFN-γ was diminished, while IL-2 and IL-6 were
more clearly discernible, especially in sera of non-treated mice.
The predominant cytokines were IL-10 and IL12, both at much
higher levels (1,215 and 2,341 pg/ml, respectively) in the placebo-
treated live vaccinated mice, compared to the live-vaccinated and
BKI-1294 treated mice (38 and 230 pg/ml, respectively). In most
instances the sera of live vaccinated and BKI-1294 treated mice
exhibited lower cytokine levels compared to non-treated mice
(see Table 4).
Effects of BKI-1294 on the Antibody
Recognition Pattern in Live-Vaccinated
Mice
BALB/c mice were live-vaccinated with N. caninum tachyzoites
and were treated either with BKI-1294 emulsified in corn oil
or with corn oil alone for 5 days, starting at 2 days p.i. At
26 days p.i., mice were euthanized and serum samples were
obtained and pooled for each group. None of the animals showed
any clinical signs during this period. For Western blot analysis,
MNCs and tachyzoite extracts were separated by SDS-PAGE
and visualized by Silver staining (Figure 5A). The reactivities
of the antisera obtained from placebo-treated and BKI-1294
treated mice were assessed by Western blotting (Figure 5B).
Alignment of the strips showed that the overall banding patterns
in all blots were similar. However, upon closer inspection we
identified 6 bands that were stained only in blots of MNC
extracts, and were absent or largely diminished in tachyzoite
blots. This led to the identification of 4 bands in MNC extracts
that were recognized by both sera (red arrows, Figure 5B), and
two bands of 90 and 38 kDa (green arrows, Figure 5B) that were
labeled only by sera from BKI-1294 treated mice. These MNC-
associated bands could not be detected in extracts of non-treated
tachyzoites. Thus, these bands and the corresponding regions in
the tachyzoite extract blots were cut out and subjected to LC-MS
and database mining for protein identification. Table 5 shows the
results of this immunoproteomics approach for the 90 and 38
kDa band. Obviously, several proteins were identified. However,
two filters were applied, namely (i) the approximate reported
molecular weight, and (ii) for each candidate antigen the ratio
of abundance in MNC vs. tachyzoite extract (MNC/T) of 2 or
above as determined for each antigen. The resulting proteins that
are overexpressed in MNCs are shown in Table 5. Overall, this
indicates that the antibody response of live-vaccinated and BKI-
1294 treated mice differed from the response of mice that were
only live-vaccinated, with specific proteins recognized in MNCs
but not in tachyzoite extracts.
DISCUSSION
In this study, we investigated the long-term effects of BKI-
1294 treatment in BALB/c mice live-vaccinated with Nc-Liv
tachyzoites with regard to safety and efficacy against re-infection
with Nc-Sp7 tachyzoites during pregnancy. The 5 days treatment
was done according to previous publications, in which the
drug was applied 2 days following primary infection, showing
highly promising efficacy in pregnant mice (19, 20). Our goal
was to reproduce these findings and then study the long-term
effects upon re-infection. While earlier studies have focused on
the efficacy of BKI-treatments in animals that were infected
during pregnancy, this is the first investigation on how BKI-
1294 affects live-vaccinated mice. As anticipated from previous
studies (20), BKI-1294 treatment applied shortly after live-
vaccination reduced the cerebral parasite load in the dams,
but had an unexpected detrimental impact on safety and
efficacy against challenge infection during pregnancy, resulting
in neonatal pup mortality and vertical transmission despite
significantly decreased cerebral parasite load. IFN-y, IL-10, and
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FIGURE 4 | Cytokine levels (pg/ml) measured in sera of N. caninum infected mice and control mice, treated or not with BKI-1294. Blood samples were collected from
the tail vein at day 11p.i. (A) and day 26 p.i. (B).
TABLE 4 | Serum cytokine levels (pg/ml) of live-vaccinated mice (pooled samples of 6 mice) taken on day 4 (d4.p.i.), day 11 (d11.p.i.), and day 26 (d26p.i. 26 p.i.), as
determined by multiplex immunoassay.
IFN y IL-1B GM CSF IL-2 IL-4 IL-6 IL-10 IL-12 MCP-1 TNFa
4d.p.i +BKI-1294 0 0 0 0 0 13.1 1.5 0 52.2 5.6
4d.p.i. –BKI-1294 0 0 0 0 0.17 9.3 3.6 0 34.9 5.6
11d.p.i. +BKI-1294 42.2 0.0 6.3 5.5 4.1 14.3 67.7 277.9 85.9 11.9
11d.p.i. –BKI-1294 253.7 1.4 6.3 10.9 12.3 46.7 94.3 234.8 83.2 16.4
26d.p.i. +BKI-1294 15.2 15.0 6.3 71.4 1.2 7.5 38.0 229.8 99.3 10.3
26d.p.i. –BKI-1294 70.4 97.8 22.7 200.8 38.4 116.7 1215.1 2340.9 231.5 17.6
Live-vaccinated mice were either treated by oral application of BKI-1294 (50 mg/kg/day for 5 days), starting on day 2 p.i.. Measurements were done using Eve Technologies’ Mouse
Focused 10-Plex Discovery Assay® (MilliporeSigma, Burlington, Massachusetts, USA).
IL-12-levels were consistently lower in live-vaccinated and BKI-
1294 treated animals compared to non-treated mice. In addition,
live vaccinated and BKI-1294 treated mice exhibited an antibody
recognition pattern inMNC extracts that was different from non-
drug-treated mice, and two protein bands in MNC extracts that
were only recognized by sera of live-vaccinated mice treated with
BKI-1294 were analyzed by proteomics.
Neospora live-vaccines are regarded as the most effective
means of preventing neosporosis in mice as well as in cattle
(1, 5, 38). Experimentally assessed live-vaccines include mostly
naturally attenuated strains of low-virulence (4, 6–8, 39), strains
that have been cultured during longer time periods and/or
were applied at a subclinical dose (40, 41), gamma-irradiated
mutants (42), a temperature sensitive strain induced by chemical
mutagenesis (43, 44), and also a genetically modified strain
(45). In this study, live-vaccination was carried out with Nc-
Liv, known to be a highly virulent strain, that is reported
to exhibit pup mortality and vertical transmission rates of
100% when inoculated into pregnant mice at dose of 2 ×
106 tachyzoites (37). However, when inoculated at the lower
dose of 105 tachyzoites (see group D), Nc-Liv did not induce
any pathology in the dams, did not affect fertility, did not
induce either neonatal nor postnatal mortality in offspring
mice, and no recrudescence or vertical transmission could
be detected. However, when Nc-Liv live-vaccinated mice were
treated with BKI-1294 (group C), neonatal mortality was
increased to 12.5% and vertical transmission was detected in
6 out of 56 pups. Although these numbers are not statistically
significant, they demonstrate that BKI-1294 treatment could
either result in increased recrudescence, or the treatment after
live-vaccination resulted in compromised immunity, allowing
the parasites to persist at low numbers and continue proliferation
during pregnancy.
In addition, while live-vaccination induced substantial
protective immunity against infection during pregnancy, this
protective effect was partially lost in the live-vaccinated and
BKI-1294 treated group A, especially with regard to vertical
transmission, with a statistically significant increase to over 21%.
Whether these congenitally infected pups were infected with
Nc-Liv (used for live-vaccination), with NcSpain-7 (used for
re-infection during pregnancy), or both, was not elucidated.
This could be done by microsatellite characterization of
PCR-positive samples. However, since vertical transmission
was also seen without re-infection during pregnancy, it is
conceivable that some of these animals were infected with
both strains.
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FIGURE 5 | Silver stained SDS-PAGE (A) and Western blot (B) of tachyzoite (T) and MNC (M) extracts, labeled with sera from live-vaccinated mice that were either not
treated (No drug) or with sera from live-vaccinated mice treated with BKI-1294 (BKI-1294). Red arrows indicate bands that are stained in MNC extract by both
antisera, green arrows are those bands labeled with serum from BKI-1294 treated mice only.
TABLE 5 | List of proteins found to be potentially present in bands specifically immunoreactive in MNC extracts, but missing in tachyzoite extracts, using antisera of
live-vaccinated and BKI-1294 treated mice.
Band MNC/T Accession No. Protein name Putative MW (kDa) Score (AA)
(kDa)
90±10 2.8 NCLIV_049900 Myosin C 93 107
29.7 NCLIV_069130 Uncharacterized protein 89 11
6.1 NCLIV_030050 Uncharacterized protein 97 55
29.7 NCLIV_007010 Cathepsin C2, putative TgCPC2 83 38
9 NCLIV_014430 Uncharacterized protein 80 22
38±4 2.5 NCLIV_056430 Solute carrier family 25, member 10, related 39 86
70.3 NCLIV_054830 Uncharacterized protein 35 114
61.2 NCLIV_066970 Putative enoyl acyl carrier reductase 42 61
Results show only those proteins that have an approximate putative molecular weight corresponding to the respective band, and are more than 2 times higher expressed in MNC
compared to tachyzoites.
Surprisingly, pup mortality and vertical transmission rates
did not correlate with the cerebral parasite burden in the dams
analyzed at the endpoint of this experiment. Group B, live-
vaccinated and treated with BKI-1294, exhibited the lowest
cerebral parasite load, confirming earlier results on in vivo
efficacy of BKI-1294 (20). Cerebral parasite loads in groups C
and D (vaccinated/re-infected and vaccinated/non-re-infected,
respectively, but both without BKI-1294 treatments), were
significantly higher. Nevertheless, these two groups exhibited
zero postnatal mortality and no vertical transmission. Analyses
of the antibody responses confirmed the impact of BKI-1294
treatments on parasite load. Measurements of IgG1 and IgG2a
on day 14 post-live-vaccination showed decreased IgG1 levels
in BKI-treated mice compared to non-treated mice, while
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IgG2a levels remained the same. IgG2a levels were also not
significantly different between the treatment groups on day
16 of pregnancy and on day 30 post-partum but significant
differences between some of the groups were detected with
respect to IgG1 levels. A comparison of the IgG1/IgG2a ratios
at day 16 of pregnancy revealed that those groups that were
live-vaccinated and re-infected (groups A and C) exhibited
a predominantly IgG1-biased response, which was much less
pronounced in group A (treated with BKI-1294 following live
vaccination). In contrast, those groups that were only live-
vaccinated without re-infection (B and D), exhibited IgG2a-
biased responses, which is indicative for a Th1 cellular immune
response. This response was slightly less pronounced in the
BKI-treated group B.
The impact of BKI-1294 on the cellular immune response
was first investigated by analyzing, in vitro, the direct effects of
BKI-1294 on the proliferative capacities of mitogen-activated B
and T cells stimulated with LPS and ConA, respectively. The
drug did not affect these cells directly. The cellular immune
response againstN. caninum infection involves first the activation
of antigen presenting cells (APCs), especially macrophages
and dendritic cells (DCs), and the expression of IFN-γ. IFN-
γ then triggers the production of high amounts of pro-
inflammatory mediators, which in turn mediate tachyzoite-to-
bradyzoite differentiation (46, 47). By analyzing recall responses
in medium supernatant of splenocytes of BKI-1294 treated and
non-treated mice collected on day 26 p.i. and stimulated with
N. caninum antigen extract, IFN-γ was indeed identified as the
by far most abundant cytokine. In sera of live-vaccinated mice,
treated or not with BKI-1294, and taken on days 4, 11 and 26
post-live vaccination, cytokine levels were very low on day 4, but
IFN-γ and the pro-inflammatory cytokine IL-12 were the most
abundant cytokines detected on day 11 p.i.. On day 26 p.i., IL-12
and the regulatory cytokine IL-10 were present at high levels in
sera of non-treated mice, but at lower levels in BKI-1294 treated
mice. IFN-γ on the other hand was almost undetectable at the
later timepoint in both treated and non-treated mice. Thus, BKI-
1294 treatment affected the Th1-biased cellular immune response
in live-vaccinated mice, probably due to its inhibitory effects on
the parasites, and this correlates well with the reduced cerebral
parasite burden as observed in group B (live-vaccinated and
treated) compared to group D (only live-vaccinated).
Following infection in an immunocompetent host, it is
expected that N. caninum tachyzoites respond to immunological
and physiological stress by differentiating into tissue cyst-
forming bradyzoites, which undergo limited proliferation
and remain viable for extended periods of time without
causing inflammatory responses (1). Recrudescence, meaning
bradyzoite-to-tachyzoite re-differentiation can then be caused by
(partial) loss of immunocompetence such as during pregnancy,
during which a shift from a Th1- to a Th2-biased immune
response takes place (48–50). However, tissue cysts and
recrudescence in chronically infected BALB/c mice has not
been detected frequently. Previous studies demonstrated that
BALB/c mice chronically infected with two isolates of different
virulence transmitted the infection to their progeny only at
a very low rate [8 and 17% of total pups, for the higher
(Nc-Sp7) and lower virulence (NcSpainH-1) isolate, respectively]
(51, 52). Thus, while N. caninum tissue cyst formation has
been generally linked to an inflammatory, Th1-biased cellular
immune response (47, 50), it is not clear whether these live-
vaccinated mice actually harbored tissue cysts. Overall, there
are few reports on tissue cyst formation in inbred mouse
strains (53). The most successful protocols designed to produce
N. caninum tissue cysts in mice involved immunosuppressed
outbred mice (e.g., ICR mice) infected with Nc-Liv, which
is known to form tissue cysts more efficiently than other
isolates (54–56).
It is possible that no tissue cysts were formed in BKI-
1294 treated mice. In vitro, BKI-1294 induces the formation
of MNCs, which contain newly formed zoites that undergo
continuous DNA replication (21). A likely scenario is that MNCs
were formed also in vivo, and this could be responsible for
the observed reactivation of the live-vaccine and the increased
vertical transmission upon re-infection. Shotgun proteomics had
shown thatMNCs exhibited an altered proteome when compared
to tachyzoites, and this drug-induced stage was termed baryzoite
(22). Following in vitro treatment with BKI-1294 during 5 days,
it took approximately 10 days of culture without drug for MNCs
to disappear and tachyzoites with SAG1 surface expression to
re-emerge (21). If similar MNCs were also formed in vivo, it is
conceivable that this could interfere in the process of cerebral
tissue cyst formation, and thus reactivation of the infection
during pregnancy could be taking place in a different manner
than in non-treated mice. However, further in vivo studies
and more detailed molecular and (immuno-)histopathological
analyses of different organs will be necessary to clarify this point.
One indication thatMNC formation did take place is provided
by the immunoproteomics approach applied in this study.
Tachyzoite and MNC extracts were separated by SDS-PAGE and
Western blots were incubated with sera from live-vaccinated and
non-treated or BKI-1294 treated mice. Alignment of Western
blots resulted in the identification of 2 bands in MNC extracts
of ∼90 and 38 kDa recognized only by sera of BKI-1294 treated
mice. LC-MS and data base mining showed that these bands
were comprised of several proteins with potentially upregulated
expression in MNCs. However, recent comparative proteomics
of N. caninum tachyzoites and MNCs did not pick up any
of these proteins as differentially expressed in the two stages
(22), indicating that their expression levels might be below the
resolution limit of the shotgun proteomics approach. In any case,
these proteins represent interesting candidates for the further
characterization of MNCs and for studies on how this drug-
induced MNC stage could interact with the host.
In conclusion, the treatment of live-vaccinatedmice with BKI-
1294 affected the cellular and humoral immune responses against
infection. While the treatment with this compound reduced the
cerebral parasite burden in live-vaccinated animals, the safety
of the live vaccine was diminished, and decreased protection
against re-infection during pregnancy was observed, while live-
vaccination without drug treatment resulted in excellent safety
and efficacy. The formation of drug-induced MNCs could be
implicated in this process. Whether similar effects can be seen
with other compounds is not yet clear and remains to be
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investigated. However, MNCs similar to those seen in this
study were reported upon in vitro treatment of T. gondii
tachyzoite-infected cells with diclazuril (57). Diclazuril is a
triazonine compound that affects mitochondrial enzymes of
the respiratory chain and other enzymes such as dihydrofolate
reductase, which is involved in nucleotide biosynthesis (58).
Potentially, the findings presented here could have implications
for the treatment with BKI-1294, and potentially other drugs,
of N. caninum infected animals that acquire re-infection during
pregnancy, and follow-up studies should be done in a more
relevant ruminant animal model.
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